Baseline PD-L1 expression on circulating immune cells as a predictor of survival and immune-related adverse events in extensive-stage small-cell lung cancer patients treated with durvalumab and carboplatin-etoposide (NCT04712903 Trial).

J Transl Med · 2026 · PMC13059145 · PMID 41764558

Europe PMC DOI

hedged sentence

0.0920

closest p · 1.8× alpha

0.0920

boldest claim

The sentences

did not reach statistical significancep = 0.092so close (0.05 < p ≤ 0.1)

OS trends mirrored PFS but did not reach statistical significance in patients with high percentages of circulating PD-L1 + monocytes: NR (95% CI NR-NR) vs. 9.13 months (95% CI 6.34 to 11.92), p = 0.092 (Supplementary Fig. 2 M).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.